GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes

Diabetes

Volumn 62, Issue 12, 2013, Pages 4174-4178

  Miao, Dongmei ^a   Guyer, K Michelle ^a   Dong, Fran ^a   Jiang, Ling ^a   Steck, Andrea K ^a   Rewers, Marian ^a   Eisenbarth, George S ^a   Yu, Liping ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN ANTIBODY;

ADOLESCENT; ANTIBODY AFFINITY; ANTIBODY DETECTION; ARTICLE; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; ELECTROCHEMILUMINESCENCE ASSAY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PROCEDURES; IMPAIRED GLUCOSE TOLERANCE; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOASSAY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SENSITIVITY ANALYSIS;

ADOLESCENT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INFANT; LUMINESCENCE; MALE; PREDIABETIC STATE; RISK; SENSITIVITY AND SPECIFICITY;

EID: 84891821090     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0534     Document Type: Article

References (13)

1. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/ IA-2 autoantibodies. Diabetes 1996;45:926-933
2. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-1710
3. Greenbaum CJ, Sears KL, Kahn SE, Palmer JP. Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: a follow-up of the Seattle Family Study. Diabetes 1999;48:170-175
4. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473-2479
5. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012; 61:179-186
6. Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013;36: 2266-2270
7. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. J Clin Endocrinol Metab 2010;95:3360-3367
8. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type. Diabetes Care 2009;32: 2269-2274
9. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597
10. Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533
11. Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJ. Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol 2012;167:67-72
12. Siljander H, Härkönen T, Hermann R, et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009;25: 615-622
13. Yu L, Rewers M, Gianani R, et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996;81: 4264-4267